AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000437
Drug: Placebo Tablet and Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00782379
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
Trial: NCT00458705
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04226105
Drug: GP40081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
Trial: NCT01872182
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily twice for 12 weeks
Trial: NCT02284854
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02070380
Drug: MultiHance 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiHance administered at 0.1 mmol/kg
Trial: NCT02070380
Drug: MultiHance 0.05 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiHance administered at 0.05 mmol/kg
Trial: NCT02553473
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02553473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002809
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002809
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04498273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Trial: NCT01517373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
Trial: NCT00470808
Drug: POMx
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01396785
Drug: 33525
RxNorm normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days
Trial: NCT01396785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days
Trial: NCT04492293
Drug: ICP-192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-192 is a white, round, uncoated table
Trial: NCT03109392
Drug: Nebulized Lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
Trial: NCT03109392
Drug: Combined spray and nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
Trial: NCT01272219
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
Trial: NCT01272219
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Trial: NCT03814629
Drug: Weifuchun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
Trial: NCT01796951
Drug: Celecoxib 200 mg BID
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
Trial: NCT02045797
Drug: GSK2140944 Lyophile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
Trial: NCT02045797
Drug: GSK2140944 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Trial: NCT01599871
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline 100 mg, twice at day
Trial: NCT03540485
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
Trial: NCT04105634
Drug: FNOS
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
Trial: NCT00077012
Drug: QLT0074
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00077012
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02775734
Drug: N-acetyl-cysteine
RxNorm normalized name: Dendrimer N-acetyl-cysteine
DrugBank: Acetylcysteine zidrimer (DB16496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
Trial: NCT01837095
Drug: POL6326
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
Trial: NCT01885338
Drug: Inactive placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04091438
Drug: TAK-925 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-925 placebo-matching IV infusion.
Trial: NCT04365270
Drug: Glass Ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass ionomer filling material would be modified accordingly or used as is
Trial: NCT02677922
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00951873
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
Trial: NCT02656173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03073070
Drug: biotin labeled RBCs
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
Trial: NCT03681093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily administered orally as tablet
Trial: NCT02267525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03113188
Drug: CBP501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501, CDDP plus Nivolumab
Trial: NCT02327143
Drug: LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02327143
Drug: ¹³C₈-LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00276380
Drug: EGb761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
Trial: NCT00276380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Trial: NCT00276380
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Trial: NCT03177798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
Trial: NCT02172651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
Trial: NCT04278924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 placebo-matching SC injection.
Trial: NCT01725282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablets
Trial: NCT04544111
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg IV every 4 weeks
Trial: NCT04652882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT03515304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Trial: NCT00980629
Drug: M516102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day
Trial: NCT00980629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day
Trial: NCT03004495
Drug: CHF5259 + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. for 14 days
Trial: NCT03004495
Drug: CHF6001 + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. for 14 days
Trial: NCT01409200
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given per standard of care
Trial: NCT03594656
Drug: Ganoderma
RxNorm normalized name: GANODERMA LUCIDUM STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8g twice daily
Trial: NCT03594656
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8g twice daily
Trial: NCT00663195
Drug: spironolactone + furosemide
RxNorm normalized name: furosemide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
Trial: NCT02349477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a pill that looks exactly like the active medication but does not contain medication
Trial: NCT04569825
Drug: Ophtamesone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local application intranasally as drops
Trial: NCT02813512
Drug: ADSCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous ADSCs
Trial: NCT00406731
Drug: Physiologic saline solution (placebo control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion over 20 minutes; twice on 1 study day
Trial: NCT02633527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered once daily
Trial: NCT02633527
Drug: 100mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg SPN-812 was administered once daily and compared to placebo
Trial: NCT02633527
Drug: 200mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Trial: NCT02633527
Drug: 300mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg SPN-812 was administered once daily and compared to placebo
Trial: NCT02633527
Drug: 400mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Trial: NCT01674361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to bitopertin once daily orally.
Trial: NCT01248468
Drug: Aspirin, acetaminophen and caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
Trial: NCT01248468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00801255
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg po bid/100mg po q8h for 7 days
Trial: NCT03813121
Drug: placebo intravenous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single placebo infusion
Trial: NCT00468546
Drug: MabThera/Rituxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1
Trial: NCT00468546
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2
Trial: NCT03867084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0.9% normal saline.
Trial: NCT01487161
Drug: TCA IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 mL intra-articular injection
Trial: NCT01269320
Drug: Femarelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
Trial: NCT00489476
Drug: Staccato Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol inhalation (0mg)
Trial: NCT02098473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619398
Drug: FK506MR capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02423954
Drug: Irinotecan + capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01608308
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
Trial: NCT01608308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
Trial: NCT01962753
Drug: 18FAV45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
Trial: NCT03288259
Drug: Local Anesthetics,Topical
RxNorm normalized name: LOCAL ANESTHETICS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
Trial: NCT04146207
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 po QD
Trial: NCT02181413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib citrate placebo-matching capsules
Trial: NCT00890656
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
Trial: NCT00890656
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 by vein (IV) over 24 hours
Trial: NCT00890656
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
Trial: NCT01924065
Drug: Oral Anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
Trial: NCT01460537
Drug: BAY80-6946
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
Trial: NCT01460537
Drug: BAY80-6964 fixed dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
Trial: NCT01444924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
Trial: NCT03662620
Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: White colored oval three-layer tablet
Trial: NCT03662620
Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: White and pink colored oval two-layer tablet
Trial: NCT00057577
Drug: Medications
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Trial: NCT02580006
Drug: EPORON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration subcutaneously
Trial: NCT02580006
Drug: EPREX
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration subcutaneously
Trial: NCT01760980
Drug: Reference product (A) Aromasin (Exemestane)
RxNorm normalized name: Aromasin Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromasin tablets will be administered under fasting conditions on two occasions
Trial: NCT02691494
Drug: Placebo for Estradiol/Norethindrone Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT02691494
Drug: Estradiol/Norethindrone Acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Trial: NCT00189878
Drug: Methotrexate (drug)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 10 to 15 mg weekly for 8 weeks
Trial: NCT00189878
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 placebo capsules - identical to capsules containing methotrexate
Trial: NCT00236197
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Trial: NCT02157337
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg (PO) once daily for 6 days
Trial: NCT01568229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT01103830
Drug: Eurartesim™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3